黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

Nat Commun. 2022-07; 
James Brett Case, Samantha Mackin, John M Errico, Zhenlu Chong, Emily A Madden, Bradley Whitener, Barbara Guarino, Michael A Schmid, Kim Rosenthal, Kuishu Ren, Ha V Dang, Gyorgy Snell, Ana Jung, Lindsay Droit, Scott A Handley, Peter J Halfmann, Yoshihiro Kawaoka, James E Crowe, Daved H Fremont, Herbert W Virgin, Yueh-Ming Loo, Mark T Esser, Lisa A Purcell, Davide Corti, Michael S Diamond
Products/Services Used Details Operation
Polyclonal Antibody Services … A CM5 chip with covalently immobilized anti-Avi polyclonal antibody (GenScript, Cat #: A00674-40) was used for surface capture of His-Avi tag containing RBDs. Running buffer was … Get A Quote

摘要

Omicron variant strains encode large numbers of changes in the spike protein compared to historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several monoclonal antibody therapies lose neutralizing activity against Omicron variants, the effects in vivo remain largely unknown. Here, we report on the protective efficacy against three SARS-CoV-2 Omicron lineage strains (BA.1, BA.1.1, and BA.2) of two monoclonal antibody therapeutics (S309 [Vir Biotechnology] monotherapy and AZD7442 [AstraZeneca] combination), which correspond to ones used to treat or prevent SARS-CoV-2 infections in humans. Despite losses in neutralization potency in cell culture, S309 or AZD7442 treatments reduced BA.1, B... More

关键词